Litcius/Paper detail

Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An <i>In Silico</i> Study

Mostafa Jamalan, Ebrahim Barzegari, Fathollah Gholami-Borujeni

2020Journal of Proteome Research27 citationsDOI

Abstract

)-1-naphthalen-1-ylethyl]benzamide showed promising affinity for the viral proteinase. All of the identified compounds demonstrated an acceptable pharmacokinetic profile. In conclusion, our findings represent rediscovery of analgesic, anti-inflammatory, antibacterial, or antiviral drugs as promising pharmaceutical candidates against the ongoing coronavirus.

Topics & Concepts

In silicoPapainComputational biologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug discoveryChemistryVirtual screeningBiologyCoronavirus disease 2019 (COVID-19)BioinformaticsBiochemistryEnzymeMedicineGeneInfectious disease (medical specialty)DiseasePathologyComputational Drug Discovery Methodsvaccines and immunoinformatics approachesSARS-CoV-2 and COVID-19 Research
Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An <i>In Silico</i> Study | Litcius